San Diego, 28 - 30 November 2018

Schedule

Create your personal agenda –check the favourite icon

Nov 2808:10
Conference pass

Keynote Opening Address: The impact of vaccine legislation on public health in California

Keynotes
Nov 2808:30
Conference pass

Addressing the epidemic of misinformation

Keynotes
  • What are the key drivers of hesitancy to vaccinate?
    • Complacency, convenience and confidence
  • What works in tackling misinformation and building trust?
    • E.g. what steps are being taken to counteract sophisticated social media campaigns of parent groups?
  • What responsibility do public health and education authorities have and how can companies get involved?
Nov 2809:20
Conference pass

How T cells control antibody responses: T follicular helper (Tfh) CD4 T cells and germinal center B cell responses to vaccines

Keynotes
Nov 2809:45
Conference pass

The evolution of antibody therapy for cancer

Keynotes
  • Progress in the development of antibody drug conjugates,bispecific antibodies, and fusion protein/antibodies
  • Novel approaches in antibody therapy- who is leading the next generation of antibody development?
  • What have been the most successful and least successful antibody therapies? Why?
  • How do we decide what level of toxicity is acceptable? Does this vary across indications?
Nov 2811:25
Conference pass

Chair’s Opening remarks

Immuno-Oncology
Nov 2811:35
Conference pass

Advantages of using oral tablet vaccines for protection against influenza

Vaccine Development
Nov 2811:35
Conference pass

Synthetic DNA vaccines for cancer immunotherapy – Enabling personalized treatments

Immuno-Oncology
Nov 2811:35
Conference pass

Designing innovative cohort adaptive sequential trials in oncology and other therapeutic areas

Clinical Trials
  • How can innovative trial design help speed the development process and make it more accurate?
  • Using one trial to address and identify the benefitting patient subpopulation
Nov 2812:05
Conference pass

Plant-derived VLPs as a Novel Approach to Addressing Unmet Needs in Influenza Prevention

Vaccine Development
  • Advanced clinical development of a plant-derived quadrivalent VLP vaccine in adults and the elderly
Nov 2812:05
Conference pass

An off-the-shelf dendritic cell vaccine candidate for treatment of CMV+ tumors

Immuno-Oncology
Nov 2812:05
Conference pass

Lung- MAP: using state-of-the-art genomic profiling to match patients to the most appropriate clinical trial

Clinical Trials
  • Overview of umbrella trials
  • What are the advantages of using this type trial design?
    • Reduction of cost, patient access, accelerated development
  • Efforts to create an immunotherapy clinical trial platform within the trial design to allow for running of multiple studies at the same time.
Nov 2812:20
Conference pass

Tools to identify, predict and prioritize vaccine candidates

Immuno-Oncology
  • Clinical challenges in cancer immunotherapy.
  • Personalized cancer vaccines have the potential to enhance the efficacy of checkpoint inhibitors but predicting them from somatic mutations is a formidable challenge
  • Overview of approach to build better vaccine cocktails.
  • Understand integrated genomics and cell-based solutions in the cancer immunotherapy space, including application of whole transcriptome analysis to characterize the tumor microenvironment and biomarker discovery approaches to predict patient response.
Nov 2812:35
Conference pass

Use of peptide antigens in immune-oncology vaccines and T-cell therapeutics

Immuno-Oncology
Nov 2812:35
Conference pass

Understanding which patients are most likely to responds using precision medicine tools – using MSI as a biomarker

Clinical Trials
Nov 2812:50
Conference pass

Leveraging the advantages of viral recognition as a cancer immunotherapy

Immuno-Oncology
  • Immunomic is addressing the challenges in I-O by applying our proven UNITE technology platform
  • LAMP-based nucleic acid immunotherapies have the potential to broaden the current use of cancer immunotherapy by complementing approved and investigational approaches.
  • LAMP-based nucleic acid immunotherapy has potential as cancer immunotherapy in two general ways:
    • Activation of the immune system against highly immunogenic tumor types, potentially amplifying the response seen with checkpoint inhibitors
    • Creation of a new, robust immune response to tumor types that don’t otherwise provoke an immune reaction, by reconfiguring a critical component of our immune system
  • Several discovery stage programs for virally driven cancers including MCC, NPC/Gastric and HCC. INDs to be filed for these programs in 2019.
Nov 2813:05
Conference pass
Nov 2814:00
Conference pass

Lunchtime presentation & book signing: “Vaccines did not cause Rachel’s Autism”

Keynotes
Nov 2814:50
Conference pass

A live attenuated pertussis vaccine to prevent disease, colonization and transmission

Vaccine Development
  • Why we need aB. pertussisvaccine that induces potentmucosal immunity
  • Relationship between colonizing nasopharyngeal infection and disease
  • Mechanism of action for a live attenuated intranasal vaccine
  • Non-human primate challenge model data
  • Clinical study results
Nov 2814:50
Conference pass

Next generation platform for the development of personalized synthetic cancer vaccines

Immuno-Oncology
  • Development of vaccine platform from concept to delivery
    • Bioinformatic immunogen design, use of long peptides and heat shock proteins
  • Challenges of working with peptides
  • Selecting the correct mutations in each patient
  • Parallel approach to selecting neoantigens represented by abnormal post-translational modifications
  • Potential for combination therapy
Nov 2814:50
Conference pass

Clinical trials in immune-oncology – What endpoints should we prioritize in different stages of development?

Clinical Trials
Nov 2815:20
Conference pass

Pertussis and Pertussis vaccines; mistakes made during a 112 year odyssey and what some of those mistakes bode for the future

Vaccine Development
  • During the 20th century, B. pertussis was extensively studied in animal model systems and many “toxins” and protective antigens were described.
  • DTaP vaccines were developed and put into general use in the USA in 1997.
  • During the last 13 years, major pertussis epidemics have occurred in the USA due to deficiencies in DTaP vaccines.
  • Two of the deficiencies are the small number of antigens and the type of cellular immune response.
  • The small number of antigens leads to linked-epitope suppression.
  • Because of linked-epitope suppression, all children who were primed by DTaP vaccines will be more susceptible to pertussis throughout their lifetimes.
Nov 2815:20
Conference pass

Overcoming tumor immune suppression using a novel retroviral replicating vector

Immuno-Oncology
  • Pre-clinical data: observations to support immune mediated mechanism of action
  • Phase 1 data in recurrent high-grade glioma: durable complete responses seen in dose escalation studies
  • Clinical Development: Food and Drug Administration Breakthrough Therapy Designation, European Medicines Agency’s PRIME designation and Phase 3 trial in recurrent glioblastoma and anaplastic astrocytoma
  • Updates in studies for solid tumors
Nov 2815:20
Conference pass

Clinical development of infectious disease vaccines using measles-based vector platform and application to immuno-oncology

Clinical Trials
Nov 2815:50
Conference pass

Updates in the clinical development of a chikungunya vaccine

Vaccine Development
  • Trends in chikungunya epidemiology
  • VLP vaccine technology
  • Updates in phase 2 clinical trials
Nov 2815:50
Conference pass

The next wave: development of BCMA CAR-T therapies for multiple myeloma

Immuno-Oncology
Nov 2815:50
Conference pass

Getting Closer to the Market: BiondVax's Universal Flu Vaccine Pivotal Phase 3 Trial

Clinical Trials
  • M-001 technology
  • Phase 3 trial protocol
  • Plans for getting to the market
Nov 2816:50
Conference pass

Progress towards licensure and deployment of a malaria vaccine

Vaccine Development
Nov 2816:50
Conference pass

Creation of off-the-shelf TCR-less CAR T cell therapies

Immuno-Oncology
Nov 2816:50
Conference pass
Nov 2817:20
Conference pass

Panel: Is there a future for arbovirus vaccines?

Vaccine Development
  • What is the current landscape for dengue, zika and other arbovirus vaccines?
  • Which other arboviruses should be prioritized for vaccine development or for improvements of the existing vaccine(s)?
  • What might emerging arboviruses look like and what improvements are needed in current vaccines?
  • Finding a better way to evaluate these vaccines before going into phase 3 trials.
  • Using human protection models to discover the keys to eliciting a protective immune response
  • How will the immune response to one virus affect that of another?
  • What are the challenges to funding and commercializing arbovirus vaccines?
Nov 2817:20
Conference pass

Strategies for the development of safer and more effective CAR-T therapies

Immuno-Oncology
  • General strategies for CAR-T cell control
  • Defining small molecule vs antibody-based targeting – why we use Ab-based targeting.
  • Deep dive into the technicalities of designing these switches to control different targets
  • Universality of the platform and potential for use in solid tumors.
Nov 2817:20
Conference pass

A year of substantial progress: clinical development of TB vaccine candidates

Clinical Trials
  • A TB vaccine is urgently needed to meet the WHO and UN goals for ending TB
  • Update on status of the overall pipeline of TB vaccine candidates
  • Substantial progress was demonstrated by the results of two efficacy trials of vaccine candidates
  • Implications of the efficacy trial results and takeaways for future candidates and trials
Nov 2817:50
Conference pass
Nov 2817:50
Conference pass

Clinical development of a subunit based congenital CMV vaccine

Clinical Trials
  • Vaccine development for CMV: High unmet medical need
  • CMV vaccine development at GSK, past and present
  • Critical challenges facing CMV vaccine developers

Create your personal agenda –check the favourite icon

Nov 2908:30
Conference pass
Nov 2908:30
Conference pass
Nov 2908:30
Conference pass

Chair’s Opening remarks

Delivery, Bioprocessing & Manufacturing
Nov 2908:40
Conference pass

CEPI Vaccine Portfolio overview

Vaccine Development
Nov 2908:40
Conference pass

Clinical development of a multi-mechanistic next generation innate immune checkpoint inhibitor that targets CD47

Immuno-Oncology
Nov 2908:40
Conference pass

Challenges of glycoprotein vaccines; the link between process design and antigenicity profiles

Delivery, Bioprocessing & Manufacturing
Nov 2908:55
Conference pass

Advantages of the TriGrid delivery system for delivery of DNA vaccines

Delivery, Bioprocessing & Manufacturing
Nov 2909:10
Conference pass

A novel approach to developing single dose and safe vaccines for emerging infectious diseases

Vaccine Development
  • In vivo production of VLPs allows them to be more readily recognized by the immune system
  • Safety and durability of vaccines demonstrated in HIV clinical trials
  • Platform can be applied to multiple vaccine targets including; Ebola, Zika and Lassa
  • Differs from other platforms as there is no need for adjuvants and is thermally and genetically stable
Nov 2909:10
Conference pass

Expanding Vaccine Effectiveness with Needle-Free Delivery

Delivery, Bioprocessing & Manufacturing
  • Commercially available Needle-free delivery systems
  • Established clinical efficacy with commercial vaccines
  • Helping Nucleic Acid based vaccines toward licensure
Nov 2909:40
Conference pass

Development of a replicating viral-vector based Lassa vaccine candidate

Vaccine Development
Nov 2909:40
Conference pass

From neoantigen conjugates, to plasmid DNA vaccines, rapid response in small scale production towards personalized medicine

Delivery, Bioprocessing & Manufacturing
Nov 2911:30
Conference pass

Challenges for next generation adjuvants

Keynotes
Nov 2911:30
Conference pass

Considerations for successful cancer immunotherapy in aged hosts

Keynotes
Nov 2911:30
Conference pass

Development of predictive biomarkers to determine optimal combinations in precision immunotherapy

Keynotes
Nov 2911:30
Conference pass

How can we improve speed, delivery and cost of next generation cancer vaccines?

Keynotes
Nov 2911:30
Conference pass

Legal considerations for partnering with government bodies, pharma and biotechs

Keynotes
Nov 2911:30
Conference pass

New approaches for assessing T-Cell responses to vaccination

Keynotes
Nov 2911:30
Conference pass

Oncolytic virus strategies; Development personalized oncolytic viral vaccines

Keynotes
Nov 2911:30
Conference pass

Prospects and challenges for development of a Group A Streptococcal Vaccine

Keynotes
Nov 2911:30
Conference pass

Surveillance systems to comprehensively monitor the use and safety of vaccines during pregnancy

Keynotes
Nov 2911:30
Conference pass

What are investors looking for in emerging biotechs?

Keynotes
Nov 2911:30
Conference pass

What are the next steps when immunotherapy trials fail after receiving accelerated approval?

Keynotes
Nov 2911:30
Conference pass

What are we doing to target potential responders or enrich for potential responders in immuno-oncology?

Keynotes
Nov 2914:10
Conference pass

Human challenge studies for universal influenza monoclonal antibodies

Vaccine Development
Nov 2914:10
Conference pass

Early clinical development of antibody drug conjugates: challenges and opportunities

Immuno-Oncology
Nov 2914:10
Conference pass

A DNA vaccine platform to rapidly produce countermeasures against emerging viral threats

Delivery, Bioprocessing & Manufacturing
  • Describe a highly scalable manufacturing process for the rapid production of DNA-based vaccines for emerging infectious diseases
  • Discuss the stability profile of our DNA-based product
  • Offer a real-life example of a rapid response to an infectious disease – Zika
Nov 2914:40
Conference pass

Development of trispecific antibodies for the treatment of HIV and potential for application to other infectious diseases

Vaccine Development
  • Background on broadly neutralizing antibodies to HIV addressing potency and breadth of coverage
  • Potential for combinations of antibodies to provide optimum coverage for therapy or prevention of HIV infection
  • Pre-clinical development and testing of a trispecific anti-HIV antibody molecule
  • Update on clinical development and testing of a trispecific anti-HIV antibody molecule
Nov 2914:40
Conference pass

Cell free protein synthesis and site-specific conjugation platforms for the development of ADCs and other antibody-based therapies: Focus on STRO-001 and STRO-002

Immuno-Oncology
Nov 2914:40
Conference pass

Pharmaceutical development and manufacturing strategies for delivering highly personalized cancer vaccines to patients

Delivery, Bioprocessing & Manufacturing
Nov 2915:10
Conference pass

Development of monoclonal antibodies against Ebola and other filoviruses

Vaccine Development
Nov 2915:10
Conference pass

Bispecific Technology for Multiple Avenues of T-cell Activation

Immuno-Oncology
  • Checkpoint bispecifics to improve therapeutic index: PD1 x CTLA4
  • Triple checkpoint blockade: LAG3 x CTLA4 bispecific plus anti-PD1
  • Checkpoint plus costim.: PD1 x ICOS
  • Potency-tuned IL15 for prolonged T cell stimulation
Nov 2915:10
Conference pass

Meeting the demand: Why continued innovation in immunotherapy manufacturing is crucial

Delivery, Bioprocessing & Manufacturing
Nov 2916:10
Conference pass

Harnessing Natural Immunity to Create Breakthrough Therapies for Infectious Diseases

Vaccine Development
  • These antibodies are isolated from individuals with natural immunity against pathogens.
  • Antibody sequences are derived from unmodified heavy and light chain human B lymphocyte sequences that have undergone ontogeny and selection inside a human body.
  • Antibodies derived as a result of a human immune response are expected to exhibit high affinity, ideal safety and pharmacokinetics.
  • XBiotech’s discovery and production technologies help bring these novel therapeutics from bench to bedside in a relatively short timeframe
Nov 2916:10
Conference pass

Bispecific therapies as monotherapies and in combination with checkpoint inhibitors

Immuno-Oncology
Dr Maria Karasarides, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals
Nov 2916:10
Conference pass

Advances in technology and ongoing challenges in the development of next generation antibody therapeutics

Delivery, Bioprocessing & Manufacturing
  • Overview of status of bispecific research – advantages of bispecific therapies vs two monotherapies
  • Alternative scaffolds for bispecific antibodies
  • Manufacturing strategies and challenges – production, engineering and stability
Nov 2916:40
Conference pass

Development of a broadly neutralizing monoclonal antibody with extended half-life technology for the prevention of RSV in all infants

Vaccine Development
  • Overview of early discovery work
  • Updates from 2 completed clinical trials
  • New work on International Network for Optimal Resistance Monitoring (INFORM) RSV in collaboration with ReSViNET
Nov 2916:40
Conference pass

Biologic and clinical activity of first in class ICOS agonist antibody in combination with checkpoint inhibitors

Immuno-Oncology
  • Preclinical rationale for development of JTX-2011, an ICOS agonist
  • Rationale for combinations with PD-1 inhibitors, CTLA-4 inhibitors, and vaccines
  • Clinical and biomarker data for JTX-2011 in patients with advanced solid tumors that supports further development
Nov 2916:40
Conference pass

Development of active immunoprophylaxis with DNA-encoded monoclonal antibodies (dMAb)

Delivery, Bioprocessing & Manufacturing
Nov 2917:10
Conference pass

Immune Dampening and Refocusing for deriving novel biologics for difficult and unmet infectious disease and oncology applications

Vaccine Development
  • Addressing the problem of evolved immunodominance in antigenic structures
  • What is deceptive Imprinting and how does it work?
    • e.g. what is its evolutionary benefit?
  • What are the immuno-chemical-physical characteristics that drive it?
    • e.g. how can these be identified today and tomorrow?
  • What processes and technologies are available to overcome this evolved pathogen survival strategy?
    • Review Immune refocusing technology
Nov 2917:10
Conference pass

Clinical evaluation of a fully human monoclonal antibody for the treatment and diagnosis of CA19-9 positive malignancies

Immuno-Oncology
Nov 2917:10
Conference pass

Rapid discovery of rare B-cells and manufacturing of mAbs with MabIGX technology

Delivery, Bioprocessing & Manufacturing
  • Application of nano-culture arrays to comprehensively screen the B-cell repertoire from convalescent patients for rare, functionally optimized B-cells
  • Immortalization and stabilization of selected B-cell using engineered fusion partner cell line to obviate the need for recombinant mAb expression from conventional mAb production cell lines

Create your personal agenda –check the favourite icon

Nov 3009:00
Conference pass
Nov 3009:00
Conference pass
Nov 3009:10
Conference pass

Single cell functionality serves as a predictive biomarker for overall survival of pancreatic cancer patients treated with GVAX vaccine

Immuno-Oncology
  • Polyfunctional Strength – the secretion of two more cytokines per cell, where the cytokine secretion intensity is tied to the cell which produced it, is a more accurate predictor of clinical outcome than flow cytometry, bulk protein analysis or gene array.
  • Single Cell Functionality has correlated with Objective Response across IO: CAR-T, Checkpoint Inhibitors and Cancer Vaccines
  • Polyfunctionality of CD4+ T-cells is a predictor of Overall Survival of patients treated with the GVAX Vaccine where post- versus pre-vaccination fold-change of the polyfunctional strength index was associated with patient overall survival (P = 0.001).
Nov 3009:10
Conference pass
Nov 3009:40
Conference pass

FluoroSpot analysis of immune memory against malaria vaccine candidate antigens

Vaccine Development
  • Benefits and possibilities of the FluoroSpot assay in vaccine research
  • Studying the kinetics of malaria-specific B-cells after infection
  • Analysis of B cell cross-reactivity against polymorphic malaria antigen MSP-2
  • What the future might hold for the FluoroSpot assay
Nov 3009:40
Conference pass

An integrated machine-learning approach for improved prediction of clinically relevant neoantigens

Immuno-Oncology
  • Current neoantigen discovery algorithms are not optimal to predict presentation to the cell surface.
  • Here, we outline a high-performing machine learning approach, trained on mass-spectrometry data, that predicts naturally processed and presented antigens.
  • The predictor is integrated with several immune parameters, such as HLA binding, in a deep learning layer to predict bone fide neoantigens.
  • We illustrate its application to significantly improve the identification of neoantigen targets for personalized cancer immunotherapy
Nov 3009:55
Conference pass

Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses in tuberculosis

Vaccine Development
Nov 3010:10
Conference pass

Investigating the effects of age and immunosenescence on influenza and vaccine-induced immunity

Vaccine Development
Nov 3010:10
Conference pass

A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States

Immuno-Oncology
  • Defining oncogenic states
  • Selecting 5-10 oncogenic states and identifying state-specific immunological targets, including immune checkpoints, neoantigens/anti-tumor epitopes, antibodies, and chimeric antigen receptors
  • Developing a multifactorial predictive model for eachoncogenic state to identify the most effective combinations
  • Validation of these perturbagens in isogenic cell systems, cancer cell lines, genetically engineered mouse models, and patient-derived xenografts
  • Insight into the development of novel treatment strategies
Nov 3010:10
Conference pass

Growing your company into a market leading organization

Funding & Partnerships
Nov 3011:40
Conference pass

The impact of immune experience on responses to infection and vaccination

Vaccine Development
  • Microbial experience alters the mouse immune system to more closely reflect the human immune system in a number of important ways
  • With microbial experience, the T cell pool is largely represented by cells of an effector/memory phenotype
  • Increasing immune experience confers a protective advantage against some infections, but not others
  • T cell directed vaccines or 'weak' priming methods are less effective after immune experience
Nov 3011:40
Conference pass

A mechanistic understanding of the generation and regulation of T cell responses can inform superior vaccine development

Immuno-Oncology
Nov 3011:40
Conference pass

Technology Showcase 1: Supercharging immunotherapy targeting infectious disease & cancer

Funding & Partnerships
Nov 3011:55
Conference pass

Technology Showcase 2: Therapeutic antibodies for neurodegenerative tauopathies

Funding & Partnerships
Nov 3012:10
Conference pass

Using predictive models to interrogate human immunity

Vaccine Development
Nov 3012:10
Conference pass

Panel: Integrating our understanding of the tumor microenvironment and the microbiome to inform the development of I-O treatment

Immuno-Oncology
  • Our current understanding the biology of the tumor microenvironment and microbiome in cancer.
  • How can we apply this to the development of novel immunotherapies?
  • Examples of data sharing efforts and industry/ academic collaborations
Nov 3012:10
Conference pass

Technology Showcase 3: A Novel VLP-Based HBV Immunotherapy to Achieve Viral Clearance Of Chronic Infection

Funding & Partnerships
Nov 3012:25
Conference pass

Technology Showcase 4: Immunotherapy-based eradication of established tumors with a systemically administered multiple Toll-like receptor agonist

Funding & Partnerships
Nov 3012:40
Conference pass

Viral changes and antibody features that could provide a possible template for vaccine design

Vaccine Development
Nov 3012:40
Conference pass

Technology Showcase 5: Leveraging the gut microbiome for the treatment of cancer

Funding & Partnerships
Nov 3012:55
Conference pass

Technology Showcase 6: Microscopic imaging of epigenetic landscape for drug discovery

Funding & Partnerships
Dr Alexey Terskikh, Co-Founder, Stelvio Oncology
Nov 3014:20
Conference pass

Accelerating progress of precision immunotherapy from laboratory to clinic through strategic collaborations

Keynotes
  • Progress through research, clinical trials and genomic analysis
  • Will these projects lead to us grouping cancers differently, e.g. according to genetic faults?
  • How are we working together to integrate this work and ensure we make therapies available to patients rapidly?
Nov 3015:20
Conference pass

Leveraging the power of AI & machine learning for accelerated vaccine & immunotherapy development

Keynotes
  • Applications of machine learning and predictive modeling
  • Using machine learning techniques to decipher the human microbiome
  • The increasing complexity of genomic data
  • How can we translate the success seen in precision medicine to chronic diseases?
  • Connecting deep phenotyping to genetics
  • Examples of collaborations and exciting new technologies.
last published: 22/Nov/18 11:45 GMT

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com